Bausch Health (formerly Valeant) has made a bid to acquire Synergy Pharmaceuticals’ business assets for US$200 M in cash. As part of the deal, Bausch is set to gain Trulance® (plecanatide), an approved gastrointestinal therapy, and dolcanatide, a Phase I asset, which will bolster the company’s existing gastrointestinal business. In a similar deal, Bausch acquired Dendreon Pharmaceuticals back in 2015 after it had filed for bankruptcy, only to sell it two years later to Sanpower for a 66% profit.